Cervical Cancer- A Review

Authors

Saima Eram¹, D Sudheer Kumar², P Kishore¹*

¹Department of Pharmacy Practice, Care College of Pharmacy Warangal Rural
²Department of Pharmaceutics, Care College of Pharmacy Warangal Rural
*Corresponding Author
Dr P. Kishore
Head, Department of Pharmacy Practice, Care College of Pharmacy, Oglapur (v), Damera (m), Warangal Rural, Telangana, India – 506006

Abstract

Cervical cancer is the third most leading cancer among women, is more prevalent in rural population. The rate and incidence of cervical cancer has declined due to HPV vaccination, screening and education. At present quadrivalent vaccine GARDASIL and bivalent vaccine CERVARIX are available in many countries where as in US the only available vaccine is GRADASIL-9 due to its more efficiency than quadrivalent and bivalent vaccine. Surgery and radiation are considered are best treatment for cervical cancer either individually or in combination. New immunotherapy has also discovered for treatment of cervical cancer.

Introduction

World-wide, cervical is considered as third most leading cancer among women in terms of new cases per year. The predominance (85%) of cervical cancer burden is in developing or less developed countries[1]. The incidence rate and death rate of cervical cancer in well developed countries has gradually declined due to cancer screening programs and Human Papillomavirus [HPV] vaccination programs sponsored by huge government budgets[2]. Today there is a superior understanding of natural history of human papillomavirus (HPV) infection and cervical carcinoma. Approximately all cases of cervical carcinoma are accompanied by chronic infection by carcinogenic HPV genotypes, which leads to progression of precancer in epithelium of cervix[3]. HPV types are classified into high risk and low risk types based on their biological properties and oncogenic potential[4].

Epidemiology

Globally, cervical cancer is considered as third most common cancer among women[1]. To an extent of 5,60,505 new cases and 2,84,923 deaths occurred in 2015. With the determinant majority of around 85% cervical cancer cases and 87% of cervical cancer deaths occur in developing areas[5]. One of the major problems faced by Indian women is cervical cancer. In India about 1,20,000 women develop cervical cancer disease per year. India contributes 15.2% of the total cervical cancer deaths in world, cervical cancer deaths are more in rural areas when compared to urban population[6].

Prevention

Cervical cancer is caused by human papilloma virus, preventing HPV infection is necessary to prevent cervical cancer. It can be achieved either by vaccination or by complete abstinence from sexual activity[7].
Two vaccines are available intended to prevent this disease. They are quadrivalent vaccine GARDASIL and a bivalent vaccine CERVARIX, quadrivalent vaccine prevents against HPV 16, 11,16 and 18 and bivalent vaccine prevents against HPV 16 and 18. These vaccines are available and marketed in many countries considering as a prophylactic measure of HPV related diseases\[5\].

Both the HPV related antibodies decrease the incidence of premalignant chances of cervix and perineum all over by 93 percent and 62 percent individually\[8\].

Most often HPV vaccination is given to age 9 to 26 while the vaccination is potent if administered before the contamination take place. The immunization came into view to be efficacious no less than 4 to 6 years\[8\].

The bivalent vaccine (CERVARIX) and the quadrivalent vaccine (GRADASIL) were discontinued in United States in 2016 and 2017 respectively. At present GRADASIL9 is only vaccine available in United States, which targets HPV types 6,11,16,18 along with 31,33,45,55,58 - these causes 90 percent of cervical cases and most cases of genital warts\[9\].

**Barrier Protection**

Protection and use of spermicidal gel during sex reduces the risk of malignant chances of cervix. In addition, condoms are supportive in treating conceivable premalignant changes of cervix\[8\].

**Screening For Early Detection of Cervical Cancer**

Screening of asymptomatic women is done for prior diagnosis of cervical cancer, with an intention of identifying and treating the precancerous lesions of the cervix as an essential step to control cervical cancer\[5\].

Various screening options like cytology, testing for high risk HPV and visual based screening methods have been inspected and implemented in various regions ubiquitously\[5\].

**Unique Characters of HPV to Interact with Host Immune System**

The unique interaction of HPV with host immune system is achieved by three basic properties of HPV. As there is no viraemic phase, immune cells present in the circulation cannot approach the virus easily. The early infection is present on the basement membrane, where Langerhans cells are abundant cells present, especially in the apical layers of mucosa. The HPV does not elicit major damage to host cells, like lysis of the infected cell, minimises the inflammation and subsequent signalling allows the virus to duplicate silently. The expression off oncogenes is at too low levels throughout its initial life cycle. Highly immuneogenic substance like L1 and L2 capsid proteins are synthesised only in outer layers of the epithelium\[10\].

**Pathway from HPV Infection to Carcinogenisis**

HPV is a non-enveloped, circular, double stranded DNA virus approximately 8 kb in size that infects basal keratinocytes. Their genomes encode eight genes from E1, E2, E4, E5, E6, E7, L1, and L2 Open Reading Frame (ORF)\[11\].

A variety of cutaneous or mucous benign or malignant lesions can be caused by HPV. In most cases the infection is non symptomatic and can be solved rapidly by participation of host immune system\[12\].

While in some cases, the infection can be latent and reactive under some conditions like immune suppression. Typically, HPV types 16 and 18 are involved, in progression of lesions into invasive cancer\[12\].

Cervical intra epithelial neoplasia (CIN) is precancerous lesion which is precursor for cervical cancer. CIN is classified as CIN-1, CIN-2 and CIN-3 based on their degree of dysplasia, named as mild, moderate and severe. These lesions are non-symptomatic and many of them get progressed into invasive cancer in certain extent of time\[12\].

The most important proteins play role in malignant transformation of HPV related lesions are E6 and E7 proteins\[12\]. The function of HPV-16 E6 is to disintegrate the tumour suppressor protein p53 by the proteasome pathway. The
tumour suppressor protein p53 gets activated during either stress condition or if DNA damage occurs, there by positively regulates expression of gene involved in apoptosis. E6 interacts with a 100 k Da cellular protein, E6AP (E6 associated protein), which act as ubiquitin protein ligase (E3)\(^{[13]}\). The E6/E6AP complex binds to p53 gene and results in ubiquitinated, gets targeted by proteasomes for degradation. As the major role of p53 is protection of integrity of genome by promoting apoptosis or cell cycle arrest, cells with the expression of HPV16 E6 protein shows chromosomal instability, which increases the chance, that the HPV infected cells will evolve towards malignancy\(^{[13]}\).

E7 is particularly found in the nucleus and the ability to bind with retinoblastoma (Rb) protein, and inactivates its function. The Rb protein has a key regulation in cell cycle. E7, modulates cell proliferation and promotes early cell entry into S-phase of the cell cycle. E7 also reacts with p21 and p27, important regulators of the cell cycle as well\(^{[12]}\).

Generally, in such conditions p53 gene mediates apoptosis. But E6 inhibits the function of p53. In combination, the two proteins promotes/lead to extensive malignant invasive lesions. Besides by supressing E6 and E7 genes, some malignant cells return to their previous benign phenotype\(^{[12]}\).

**Treatment of Cervical Cancer**

At present three therapeutic modalities are used, they are surgery, radiotherapy, hormone chemotherapy. The first two modes surgery and radiotherapy are dominant both individually and in combination. Surgery is only therapeutic approach in preinvasive and microinvasive stage (stage Ia) of cervical carcinoma. Surgery and radiotherapy are used combinedly in Ib and IIa stages, radiation alone is used in IIb, IIIa, IIIb and Iva. In IVb, chemotherapy and locoregional radiotherapy are used\(^{[14]}\).

It is accepted nearly in all oncology and radiology centres of world that combined therapy for cervical cancer is most efficacious. Intracavity brachytherapy and teleradiotherapy are combined. The first step is to destroy the malignant tissue at the cervix and its instant surroundings, while others are demolishing secondary deposits in the area of parametrium, regional and juxta regional lymph nodes and other organs of small pelvis\(^{[14]}\).

**Role of Bile Acids in Treatment of Cervical Cancer**

HS-1183, HS-1199, and HS-1200 are synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid used in treatment of cervical cancer. Further, increase in p21 WAF1/CIP1 by synthetic bile acids was dynamically accompanied with proliferating cell nuclear antigen (PCNA), which is needed for the process of DNA synthesis by DNA polymerase\(^{[14]}\). Treatment with natural products are suitable control of cervical cancer, which show reduced harmful effects. HS-1199, HS-1200, HS-1183 induced apoptosis in SiHa cells in a dose dependent mode. It is very essential that the synthetic derivatives of chenodeoxycholic acid and ursodeoxycholic acid are able to inhibit cell proliferation and inducing apoptosis in SiHa cells\(^{[14]}\).

**Immune Therapy in Cervical Cancer**

Cytotoxic T-lymphocyte associated Antigen – 4 (CTLA-4), the first immune check point receptor, expressed on t-cells, capable of down regulation T-cell activation, to prevent over stimulation of the immune system. CTLA-4 has more affinity toward the B7 complex than CD28 targeting this immune check point can increase antitumor immunity. Preclinical findings encourage the production and clinical testing of fully humanised CTLA-4 antibodies. Example: ipilimumab\(^{[15]}\). Programmed cell death protein 1 (PD-1) is also an immune check point receptor, that can induce major immune resistance by supressing the activity of T-cell in peripheral tissue during the time of inflammatory response of infection. Pembrolizumab is a highly selective humanised monoclonal IgG-A kappa isotope antibody targeting PD-1\(^{[15]}\).
Immune Therapy Besides Pembrolizumab in Cervical Cancer

Table 1 Selected ongoing trials of immune-checkpoint inhibitors in cervical cancer\(^{15}\).

| Agents             | Targets  | Phase | Indication                                                                 |
|--------------------|----------|-------|-----------------------------------------------------------------------------|
| pembrolizumab      | PD-1     | II    | Multiple types of advanced solid tumors                                     |
| pembrolizumab      | PD-1     | II    | Advanced cervical cancer, in combination with chemoradiation               |
| Durvalumab Tremelimumab | PD-L1  | I     | Advanced solid tumors, including advanced cervical cancer                   |
| Atezolizumab Carboplatin Cyclophosphamide | PD-L1 CTLA-4 | lb | Advanced breast cancer and gynecologic cancer                               |
| Ipilimumab         | CTLA-4   | I     | FIGO stage IB2/IIA with positive para-aortic lymph nodes; cervical cancer following chemoradiation |
| Nivolumab          | PD-1     | II    | HPV-16-positive incurable solid cancers, treatment naïve or in second line, including HPV-16-included cervical cancer |
| Atezolizumab Bevacizumab | PD-1  | II    | Persistent, recurrent or metastatic cervical cancer                         |
| Ipilimumab         | CTLA-4   | II    | Metastatic or recurrent HPV-related cervical cancer                         |
| Nivolumab          | PD-1     | II    | Persistent, recurrent or metastatic cervical cancer                         |

Conclusion
Cervical cancer is third most leading cancer among women, causing roughly 200,000 deaths and 500,000 new cases per annum. The incidence of cervical cancer is more in developing population when compared to developed areas. This can be overcome by early detection and appropriate treatment to infected women and by creating awareness among people. HPV vaccination also plays a huge role in reducing incidence of cervical cancer.

References
1. Prabhdeep Kaur, Ravi Mehrotra, Human papillomavirus vaccine for cancer cervix prevention: Rationale and recommendations for implementation in India Indian Journal of Medical Research, August 2017, DOI: 10.4103/ijmr
2. Zheng Hu, Ding Ma The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications Department of Gynecological oncology 21 March 2018
3. Phillip E. Castle Dan Murokora Treatment of Cervical intraepithelial lesions International Journal of Gynecology and obstetrics 2017 DOI: 10.1002
4. Birgitte Baldur-Felskov, Christian Dehlendorff Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia- Nationwide Follow-Up of Yound Danish Women Vol.106, Issue 3 March 12, 2014
5. Gauravi A. Mishra Sharmila A. Pimple Prevention of Cervix Cancer in India Department of Preventive Oncology July 28, 2016
6. Anand Narain Srivastava, Jata Shankar Misra, Cervical cancer screening in rural India: status and current concepts . Indian journal of medical research, December 2018, DOI:10.4103/ijmr.
7. Aswathy Sreedevi, Reshma Javed, Epidemiology of cervical cancer with special focus on India, International Journal of Women’s Health 2015, unported, v3.0
8. Ashlesha Deverakonda and Neha Gupta, Diagnosis and Treatment of Cervical cancer: A Review, Research and Review Journal of Nursing and Health Sciences Accepted: 6/09/2016
9. Salina Zhang, BS, Human Papillomavirus in 2019: An update on cervical cancer prevention and screening guidelines, Cleveland Clinic Journal of Medicine Volume 86. Number 3, March 2019, DOI: 10.3949/ccjm.
10. Efthimios Deligeoroglou, Aikaterini Giannouli, HPV Infection: Immunological Aspects and Their Utility in Future Therapy, Infectious Diseases in Obstetrics and Gynecology volume 2013, Accepted 18 July 2013.
11. Okechukwu A. Ibeanu, Molecular Pathogenesis of Cervical Cancer February 1, 2011, Cancer Biology and therapy DOI: 10.4161/cbt.
12. Simona Roxana Georgescu, Cristina Iulia Mitran, New Insights in the Pathogenesis of HPV Infection and the Associated Carcinogenic Processes: The Role of Chronic Inflammation and Oxidative Stress, Journal of Immunology Research Volume 2018 Published 27 August 2018
13. Raffaella Ghittoni, Rosita Accardi, Role of Human Papillomavirus in Carcinogenesis, eCancer Medical Science, Published 29/04/2015, DOI: 10.3332/ecancer.
14. Tanja Sarenac and Momir Mikov, Cervical Cervical Cancer, Different Treatments and Importance of Bile Acids as Therapeutic Agents in This Disease, Frontiers in Pharmacology, Published 04 June 2019, DOI: 10.3389/fphar.
15. Edith Borcoman and Christophe Le Tourneau, Pembrolizumab in cervical cancer: latest evidence and clinical usefulness, Therapeutic Advances in Medical Oncology, There Advance Medical Oncology 2017, Vol 9, revised manuscript accepted: 18 April 2017.